Related Experiment Video

Updated: Nov 30, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K

Apatinib as an alternative therapy for advanced hepatocellular carcinoma

Xi-Hao Zhang1, Man-Qing Cao2, Xiu-Xiu Li1

  • 1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

World Journal of Hepatology
|November 17, 2020
PubMed

Insights

Apatinib, a tyrosine kinase inhibitor, targets vascular endothelial growth factor receptor 2 to reduce tumor angiogenesis. It shows promise for treating advanced hepatocellular carcinoma (HCC).

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Angiogenesis is crucial for tumor growth and development.
  • Tyrosine kinase inhibitors targeting vascular endothelial growth factor (VEGF) are established anti-angiogenic therapies.
  • Hepatocellular carcinoma (HCC) is a significant global health concern.

Purpose of the Study:

  • To review the clinical research of apatinib in hepatocellular carcinoma (HCC).
  • To explore the application prospects of apatinib for HCC treatment.

Main Methods:

  • Review of clinical studies on apatinib in HCC.
  • Analysis of apatinib's mechanism of action as a VEGF receptor 2 inhibitor.

Main Results:

  • Apatinib demonstrates specific inhibition of vascular endothelial growth factor receptor 2.
  • Encouraging anti-tumor effects observed in various cancers, including advanced HCC.
  • Clinical data suggests potential efficacy in HCC treatment.

Conclusions:

  • Apatinib is a promising targeted therapy for advanced HCC.
  • Further clinical research is warranted to establish its role in HCC management.
Keywords:
AngiogenesisApatinibHepatocellular carcinomaVascular endothelial growth factor receptor 2

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

874
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
331
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
297